Cargando…
Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib—Preliminary Study
Background: Cutaneous melanoma is a heterogeneous tumor with a rapidly switching molecular and cellular phenotype. The invasive phenotype switching characterized by MITF(low)/AXL(high) predicts early resistance to multiple targeted drugs in melanoma. Celecoxib proved to be a valuable adjuvant in cut...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369555/ https://www.ncbi.nlm.nih.gov/pubmed/35956175 http://dx.doi.org/10.3390/jcm11154560 |